OPUS GENETICS INC (IRD) Stock Fundamental Analysis

NASDAQ:IRD • US67577R1023

3.64 USD
+0.25 (+7.37%)
At close: Feb 13, 2026
3.6317 USD
-0.01 (-0.23%)
After Hours: 2/13/2026, 8:17:54 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

IRD gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. IRD has a bad profitability rating. Also its financial health evaluation is rather negative. IRD is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year IRD has reported negative net income.
  • IRD had a negative operating cash flow in the past year.
  • IRD had negative earnings in 4 of the past 5 years.
  • IRD had negative operating cash flow in 4 of the past 5 years.
IRD Yearly Net Income VS EBIT VS OCF VS FCFIRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

  • IRD has a Return On Assets of -188.81%. This is amonst the worse of the industry: IRD underperforms 87.19% of its industry peers.
  • The Return On Equity of IRD (-1143.00%) is worse than 79.54% of its industry peers.
Industry RankSector Rank
ROA -188.81%
ROE -1143%
ROIC N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IRD Yearly ROA, ROE, ROICIRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IRD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IRD Yearly Profit, Operating, Gross MarginsIRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • IRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IRD has more shares outstanding than it did 1 year ago.
  • IRD has more shares outstanding than it did 5 years ago.
  • IRD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IRD Yearly Shares OutstandingIRD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
IRD Yearly Total Debt VS Total AssetsIRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -4.54, we must say that IRD is in the distress zone and has some risk of bankruptcy.
  • IRD has a Altman-Z score (-4.54) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.18 indicates that IRD is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.18, IRD is doing worse than 64.82% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Altman-Z -4.54
ROIC/WACCN/A
WACC12.3%
IRD Yearly LT Debt VS Equity VS FCFIRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • IRD has a Current Ratio of 1.23. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.23, IRD is doing worse than 83.37% of the companies in the same industry.
  • IRD has a Quick Ratio of 1.23. This is a normal value and indicates that IRD is financially healthy and should not expect problems in meeting its short term obligations.
  • IRD's Quick ratio of 1.23 is on the low side compared to the rest of the industry. IRD is outperformed by 82.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23
IRD Yearly Current Assets VS Current LiabilitesIRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • IRD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.85%, which is quite impressive.
  • The Revenue has grown by 74.60% in the past year. This is a very strong growth!
  • IRD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 165.10% yearly.
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
Revenue 1Y (TTM)74.6%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%

3.2 Future

  • Based on estimates for the next years, IRD will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.10% on average per year.
  • The Revenue is expected to grow by 39.65% on average over the next years. This is a very strong growth
EPS Next Y38.11%
EPS Next 2Y26.29%
EPS Next 3Y16.31%
EPS Next 5Y11.1%
Revenue Next Year48.43%
Revenue Next 2Y40.3%
Revenue Next 3Y31.21%
Revenue Next 5Y39.65%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IRD Yearly Revenue VS EstimatesIRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
IRD Yearly EPS VS EstimatesIRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • IRD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRD Price Earnings VS Forward Price EarningsIRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRD Per share dataIRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IRD's earnings are expected to grow with 16.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.29%
EPS Next 3Y16.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • IRD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OPUS GENETICS INC

NASDAQ:IRD (2/13/2026, 8:17:54 PM)

After market: 3.6317 -0.01 (-0.23%)

3.64

+0.25 (+7.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-30
Inst Owners21.31%
Inst Owner ChangeN/A
Ins Owners6.33%
Ins Owner Change-4.58%
Market Cap251.01M
Revenue(TTM)14.63M
Net Income(TTM)-68.20M
Analysts81.43
Price Target7.88 (116.48%)
Short Float %1.89%
Short Ratio1.68
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-24.18%
Min EPS beat(2)-90.4%
Max EPS beat(2)42.04%
EPS beat(4)3
Avg EPS beat(4)-7.07%
Min EPS beat(4)-90.4%
Max EPS beat(4)42.04%
EPS beat(8)3
Avg EPS beat(8)-59.5%
EPS beat(12)5
Avg EPS beat(12)-24%
EPS beat(16)8
Avg EPS beat(16)-16.12%
Revenue beat(2)0
Avg Revenue beat(2)-15.16%
Min Revenue beat(2)-29.45%
Max Revenue beat(2)-0.87%
Revenue beat(4)2
Avg Revenue beat(4)12.9%
Min Revenue beat(4)-29.45%
Max Revenue beat(4)42.31%
Revenue beat(8)3
Avg Revenue beat(8)-8.15%
Revenue beat(12)6
Avg Revenue beat(12)22.35%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.93%
PT rev (3m)13.64%
EPS NQ rev (1m)2.04%
EPS NQ rev (3m)2.7%
EPS NY rev (1m)1.69%
EPS NY rev (3m)-20.67%
Revenue NQ rev (1m)3.44%
Revenue NQ rev (3m)-7.08%
Revenue NY rev (1m)1.01%
Revenue NY rev (3m)-3.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.15
P/FCF N/A
P/OCF N/A
P/B 42.07
P/tB 42.07
EV/EBITDA N/A
EPS(TTM)-0.83
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS0.21
BVpS0.09
TBVpS0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -188.81%
ROE -1143%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.02%
ROA(5y)-98.94%
ROE(3y)-68.78%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -4.54
F-Score2
WACC12.3%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.79%
EPS Next Y38.11%
EPS Next 2Y26.29%
EPS Next 3Y16.31%
EPS Next 5Y11.1%
Revenue 1Y (TTM)74.6%
Revenue growth 3Y165.1%
Revenue growth 5YN/A
Sales Q2Q%-20.38%
Revenue Next Year48.43%
Revenue Next 2Y40.3%
Revenue Next 3Y31.21%
Revenue Next 5Y39.65%
EBIT growth 1Y-25.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year128.22%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-242.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-242.06%
OCF growth 3YN/A
OCF growth 5YN/A

OPUS GENETICS INC / IRD FAQ

Can you provide the ChartMill fundamental rating for OPUS GENETICS INC?

ChartMill assigns a fundamental rating of 2 / 10 to IRD.


Can you provide the valuation status for OPUS GENETICS INC?

ChartMill assigns a valuation rating of 0 / 10 to OPUS GENETICS INC (IRD). This can be considered as Overvalued.


How profitable is OPUS GENETICS INC (IRD) stock?

OPUS GENETICS INC (IRD) has a profitability rating of 0 / 10.


What is the financial health of OPUS GENETICS INC (IRD) stock?

The financial health rating of OPUS GENETICS INC (IRD) is 2 / 10.